Pyxis Oncology (PYXS) EBIAT (2024 - 2025)
Pyxis Oncology (PYXS) has disclosed EBIAT for 2 consecutive years, with -$22.0 million as the latest value for Q3 2025.
- On a quarterly basis, EBIAT fell 3.79% to -$22.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$97.0 million, a N/A change, with the full-year FY2024 number at -$77.3 million, down 4.78% from a year prior.
- EBIAT was -$22.0 million for Q3 2025 at Pyxis Oncology, down from -$18.3 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$3.3 million in Q1 2024 to a low of -$35.5 million in Q4 2024.